Sorafenib and TRC105 in Hepatocellular Cancer

Sponsor
National Cancer Institute (NCI) (NIH)
Overall Status
Completed
CT.gov ID
NCT01306058
Collaborator
(none)
27
1
1
75.9
0.4

Study Details

Study Description

Brief Summary

Background:

Sorafenib is a drug that has been approved to treat kidney and liver cancer (hepatocellular carcinoma, or HCC) and has been shown to prolong survival in patients with HCC. It works by slowing the spread of cancer cells, but it does not fully prevent the cancer from growing again. Researchers are interested in combining sorafenib with the experimental drug TRC105, which has been designed to block the growth of blood vessels that lead to tumor growth, in order to determine whether this drug combination stops tumor growth and reduces tumor size better than sorafenib alone.

Objectives:

To determine the safety and effectiveness of the combination of sorafenib and TRC105 as a treatment for hepatocellular cancer that has not responded to other treatments.

Eligibility:

Individuals at least 18 years of age who have been diagnosed with hepatocellular cancer that has not responded to other treatments, and who are not considered to be candidates for liver transplantation. Patients cannot be receiving anticoagulant therapy with the exception of low dose aspirin. No history of bleeding problems or peptic ulcer disease.

Design:

Participants will be screened with a full medical history and physical examination, blood and urine tests, and tumor imaging studies. Participants will have a tumor biopsy or provide previously collected tumor tissue for study. An examination of the esophagus to look for problems with blood vessels will be completed in patients with a history of cirrhosis.

Participants will receive sorafenib tablets twice every day, in the morning and at night, with a full glass of water.

Participants will receive TRC 105 infusions once every two weeks on days 1 and 15 of a 28 day cycle.

At each visit during the first cycle, participants will have a physical examination and blood tests. Participants will continue to have blood tests and a urine test every cycle to monitor the effects of treatment, including tests of kidney function. Participants will have imaging studies after every two cycles to evaluate the results of treatment, and may also provide tumor samples for study.

Treatment will continue as long as the tumor does not grow and side effects remain tolerable.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Detailed Description

Background:
  • Worldwide, hepatocellular carcinoma (HCC) is the fifth most common malignancy with a median survival of 6-9 months. The Study of Heart and Renal Protection (SHARP) study established sorafenib as a standard consideration in this disease and set the bar for future studies of systemic therapy.

  • TRC105 is a chimeric anti-angiogenic monoclonal antibody that binds cluster of differentiation 105 (CD105), a transmembrane receptor selectively expressed by proliferating endothelial cells. TRC105 binds to CD105-expressing endothelial cells and mediates growth inhibition, apoptosis and antibody-dependent cell-mediated cytotoxicity (ADCC).

Objectives:
Primary:
  • Phase I: To establish the maximum tolerated dose (MTD) of TRC105 when given with standard-dose sorafenib for HCC.

  • Phase II:To determine the estimate response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria for the combination of TRC105 with sorafenib in HCC.

Eligibility:
  • Histologically or cytologically confirmed diagnosis of HCC.

  • Childs-Pugh A or B (7 points) cirrhosis is allowed.

  • Patients must have disease that is not amenable to potentially curative resection, radiofrequency ablation, or liver transplantation.

  • In phase I, prior systemic therapy is allowed.

  • In phase II, prior systemic therapy for HCC (including sorafenib) is allowed.

  • No history of bleeding varices in previous 1 year (unless subsequent liver transplant).

  • No anti-coagulation (except low-dose aspirin).

Design:
  • TRC105 will be administered intravenously every two weeks, on days 1 and 15 of each 28 day cycle. Sorafenib will be self-administered twice daily by mouth.

  • Phase 1: The first part of this study was a standard 3+3 dose escalation phase I study with the primary objective of establishing MTD for TRC105 when given in combination with standard-dose sorafenib. Sorafenib is taken orally at a dose of 400 mg twice daily. TRC105 is administered as an intravenous infusion every two weeks. Patients will be restaged including imaging studies to assess for response and progression every 8 weeks. The TRC105 dose was escalated in cohorts of 3 to 6 patients up to a maximum of 15 mg/kg every two weeks. Intra-patient dose escalation was not allowed.

  • Phase II: TRC105 will be administered as an intravenous infusion every two weeks at the recommended phase II dose, 15 mg/kg of TRC105 ever two weeks in combination with standard dose sorafenib, defined in phase I. The sample size and interim stopping rule will be determined using a Simon optimal two-stage design. The first stage will initially enroll 6 evaluable patients, and if 0 of the 6 have a clinical response, then no further patients will be accrued. If 1 or more of the first 6 patients has a clinical response, then accrual would continue until a total of 23 patients have been enrolled. As it may take several weeks to determine if a patient has experienced a response, a temporary pause in the accrual may be necessary to ensure that enrollment to the second stage is warranted. If there are 1 to 2 clinical responses in 23 patients, this would be an uninterestingly low response rate. If there were 3 or more complete responses in 23 patients (13.0%), this would be sufficiently interesting to warrant further study in later trials. Under the null hypothesis (5% response rate), the probability of early termination is 73.5%.

Cohort: -0; Sorafenib (mg by mouth (PO) twice daily): 400 bid; TRC105 (mg/kg intravenous (IV) weekly): 1

Cohort: 1; Sorafenib (mg PO twice daily): 400 bid; TRC105 (mg/kg IV weekly): 3

Cohort: 2; Sorafenib (mg PO twice daily): 400 bid; TRC105 (mg/kg IV weekly): 6

Cohort: 3; Sorafenib (mg PO twice daily): 400 bid; TRC105 (mg/kg IV weekly): 10

Cohort: 4; Sorafenib (mg PO twice daily): 400 bid; TRC105 (mg/kg IV weekly): 15

Study Design

Study Type:
Interventional
Actual Enrollment :
27 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)
Actual Study Start Date :
Feb 11, 2011
Actual Primary Completion Date :
Jun 1, 2016
Actual Study Completion Date :
Jun 9, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sorafenib & TRC105 in Hepatocellular CA

CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day

Drug: TRC 105
15 mg/kg intravenous (IV) every 2 weeks

Drug: Sorafenib
400 mg twice a day (bid) continuously in a 28 days cycle
Other Names:
  • Nexavar
  • Outcome Measures

    Primary Outcome Measures

    1. Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) [Completed in the first 28 days of treatment (cycle 1)]

      MTD is the highest dose studied for which the incidence of DLT was less than 33%. DLT criteria included treatment-related grade 3 non-hematological toxicities or grade 4 hematological toxicities occurring within the first 28 days of treatment. Grade 3 electrolyte toxicities to be corrected to Grade 1 or less within 24 hours will be considered dose limiting (proteinuria >3.5g/24 hour will be defined as a DLT). Drug-related Grade 4 hematological toxicity will be considered dose limiting. Toxicity requiring a dose reduction or a delay in treatment for >7 days will be considered dose limiting. Other Grade 3 or higher toxicity related to TRC105 will be considered dose limiting.

    2. Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC) [2 years]

      TTP is the time between the first day of treatment to the day of disease progression. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).

    Secondary Outcome Measures

    1. Overall Response Rate (ORR) as Determined by the Standard Response Evaluation Criteria in Solid Tumors (RECIST) Criteria [2 years]

      Overall response (Complete Response (CR) + Partial Response (PR) was assessed by the Standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria for target lesions and assessed by magnetic resonance imaging (MRI). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter of target lesions.

    2. Overall Response Rate (ORR) as Determined by the European Association for the Study of the Liver (EASL)-Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria [2 years]

      Overall response (Complete Response (CR) + Partial Response (PR) was assessed by the European Association for the Study of the Liver (EASL)-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for target lesions and assessed by magnetic resonance imaging (MRI). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter of target lesions.

    3. Patients Who Developed Antidrug Antibodies [Cycle 1 Day 1, 28 days post end of study (up to 2 years)]

      Patients who develop antidrug antibodies is measured by human anti-chimeric antibody (HACA) formation (e.g. immunogenicity of TRC105).

    4. Immunogenicity of TRC105 as Measured by Human Anti-mouse Antibody (HAMA) Formation [Baseline and then 28 days following the end of the study treatment, approximately two years]

      A 5mL blood sample will be collected to assess immunogenicity. Immunogenicity will be measured by the enzyme-linked immunosorbent assay (ELISA) and expressed in titres. The higher the titre, the higher the formation of HAMA antibody in the blood. A higher concentration of HAMA (higher titre result) is a negative finding. A higher level means the drug elimination is faster and the TRC 105 is then less effective. Lower level is 0-2 titre. Any value above 2 titre would be a positive HAMA result. The HAMA ( Human anti-mouse antibody) measurement at 28 days post treatment levels provides information as to the rate of drug elimination and effectiveness. Patients with 0 to < 2.0 titre. eliminates the TRC 105 slower and the drug may be more effective than patients who have a low(>2.0 titres) or high level of HAMA. Higher levels of HAMA reflect the TRC 105 elimination from the body faster and the drug potentially not as effective as negative HAMA titres.

    5. Number of Participants With Serious and Non-serious Adverse Events by Common Terminology Criteria in Adverse Events (CTCAE)v4.0 [4 years and 10.5 months]

      Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    6. Number of Participants With Dose Limiting Toxicity (DLT) [First 28 days of treatment (cycle 1)]

      DLT was assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0. DLT criteria included treatment-related grade 3 non-hematological toxicities or grade 4 hematological toxicities occurring within the first 28 days of treatment. Grade 3 electrolyte toxicities to be corrected to Grade 1 or less within 24 hours will be considered dose limiting (proteinuria >3.5g/24 hour will be defined as a DLT). Drug-related Grade 4 hematological toxicity will be considered dose limiting. Toxicity requiring a dose reduction or a delay in treatment for >7 days will be considered dose limiting. Other Grade 3 or higher toxicity related to TRC105 will be considered dose limiting.

    7. Treatment-emergent Adverse Events [4 years and 10.5 months]

      Here are the number of treatment-emergent adverse events categorized by Any grade, Grade 3, Grade 4 and Grade 5 adverse events. Adverse events was assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0. Grade 1 is mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 is moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) (e.g. preparing meals, shopping for groceries or clothes). Grade 3 is severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL (e.g. bathing, dressing and undressing). Grade 4 is life-threatening consequences; urgent intervention indicated. Grade 5 is death related to adverse event.

    8. Median Progression-free Survival (PFS) [up to 6 months]

      PFS was calculated from the on-study date until date of progression, death, or an event that would render the patient inevaluable for further follow-up (liver dysfunction), or end of study. Probabilities were determined using the Kaplan-Meier method. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).

    9. Percentage of Participants With Progression Free Survival (PFS) at 3 and 6 Months [3 and 6 months]

      Percentage of participants who were progression free at 3 and 6 months. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).

    10. Median Overall Survival (OS) [up to 2 years]

      OS was calculated from the on-study date until the date of death or the date the patient was last known to be alive. Probabilities were determined using the Kaplan-Meier method.

    11. Percentage of Participants With Overall Survival (OS) at 6 and 12 Months [6 and 12 months]

      Percentage of participants last known to be alive at 6 and 12 months.

    12. Number of Participants With Stable Disease, Partial Response, and Progressive Disease on Phase I and Phase II of the Clinical Trial [Every 8 weeks, up to 180 days]

      Response is defined as per the Response Evaluation Criteria in Solid Tumors (RECIST). Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. To be assigned a confirmed PR, changes in tumor measurements must be confirmed by repeat assessments that should be performed at least 4 weeks after the criteria for response are first met. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).

    13. Area Under the Plasma Concentration [Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, and prior to start of TRC105 infusion]

      Mean peak TRC105 serum trough concentrations were plotted over time by dose level to assess accumulation. (e.g. drug absorption). The lower limit of quantification (LLOQ) is 200 ng/mL.

    14. Changes in Biomarkers Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF) [Cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, or end of study, an average of 12 weeks]

      Plasma biomarker tests were performed for VEGF and PIGF using assay plates from Meso-Scale Discovery according to the product manual. The concentrations of the cytokines were determined with recombinant standards. Changes in biomarkers were determined by a Wilcoxon signed rank test.

    15. Changes in Biomarker Cluster of Differentiation 105 (CD105) [Cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, or end of study (eos), an average of 12 weeks]

      Blood samples were collected and analyzed by the enzyme-linked immunosorbent assay (ELISA). Serum samples were measured using a validated ELISA with a lower limit of quantification (LLOQ) of 200 ng/ml. Soluble endoglin was only assessed in patient samples without detectable TRC105 concentrations.

    16. Percentage Signal Change in Response on Magnetic Resonance Imaging (MRI) [Baseline and Cycle 1 Day 2 and Cycle 2 Day 1, an average of 12 weeks]

      The perfusion of tumors was evaluated and analysis of normalized signal intensity in unenhanced and enhanced MRIs at each time point with calculation of measured percentage of signal change to reflect tumor vascularity. Signal change and signal intensity is defined as the Initial Area Under the Gd Curve measured over 60 seconds (IAUC60) and the Transport Constant (Ktrans) and the difference in these values relative to baseline.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA:

    • Patients must have histopathological confirmation of hepatocellular carcinoma (HCC) by the Laboratory of Pathology of the National Cancer Institute (NCI) prior to entering this study.

    Or

    histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of HCC.

    • Patients must have disease that is not amenable to potentially curative resection or ablative techniques. In addition, disease must not be amenable to or have progressed on transhepatic arterial chemoembolization (TACE). Patients must not be considered potential candidates for liver transplantation. This determination will be made after hepatobiliary surgical input at the NCI multidisciplinary conference.

    • If liver cirrhosis is present, patient must have a Child-Pugh A classification.

    • Patients with cirrhosis must have had esophagogastric endoscopy within the previous 6 months prior to study entry for the assessment of varices. If the patient has not had this done they must be willing to undergo this procedure prior to study entry.

    • Age greater than or equal to 18 years

    • Life expectancy of greater than 3 months.

    • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

    • Patients must have normal organ and marrow function as defined below:

    • Absolute neutrophil count greater than or equal to 1,500/mcL

    • Platelets greater than or equal to 60,000/mcL without transfusion support within the past 30 days

    • Total bilirubin less than or equal to 3 mg/dl.

    • Aspartate aminotransaminase (AST)/alanine aminotransaminase (ALT) less than or equal to 10 times upper limit of normal

    • Creatinine less than or equal to 1.5 times upper normal limits OR creatinine clearance greater than or equal to 40mL/min/1.73 m^2 for patients with creatinine levels above institutional normal, as calculated by the Cockcroft Gault formula.

    • Patients must have recovered from any acute toxicity related to prior therapy, including surgery. Toxicity should be less than or equal to grade 1 or returned to baseline.

    • Patients must not have other invasive malignancies within the past 5 years (with the exception of non-melanoma skin cancers or non-invasive bladder cancer).

    • Patient must be able to understand and willing to sign a written informed consent document.

    Additional Inclusion Criteria for PHASE I Portion:
    • Patients may have measurable or evaluable disease only.

    • Prior therapy: prior systemic therapy with sorafenib is allowed.

    Additional Inclusion Criteria for PHASE II Portion:
    • All patients will be required to have measurable disease.

    • Prior therapy: prior systemic therapy with sorafenib is allowed.

    EXCLUSION CRITERIA:
    • Patients who have had chemotherapy (other than sorafenib treatment), large field radiotherapy, or major surgery must wait 4 weeks prior to entering the study.

    • Patients may not be receiving any agents not approved by the Food and Drug Administration (FDA) within the past 4 weeks.

    • Patients with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

    • Proteinuria, as demonstrated by a 24-hour protein of greater than or equal to 2000 mg. Urine protein will be screened by urine protein-creatinine ratio (UPC). For UPC ratio greater than 1.0, a 24-hour urine protein will need to be obtained and the level should be less than 2000 mg for patient enrollment.

    • Uncontrolled intercurrent illness including, but not limited to, hypertension (systolic blood pressure (BP) greater than 140, diastolic BP greater than 90), ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements.

    • No anti-coagulation therapy is allowed with the exception of low-dose aspirin.

    • No bleeding diathesis.

    • Patients with a history of bleeding varices in previous 1 year are excluded (unless patient has subsequently had a liver transplant. Those with gastric varices or varices that are deemed as high risk by the endoscopist should be placed on appropriate medical therapy as advised by the gastroenterologist.

    • History of peptic ulcer disease or gastritis within 6 months of TRC105 administration, unless patient has received adequate treatment for peptic ulcer disease and has evidence of complete resolution documented by esophagogastroduodenoscopy (EGD). Mild gastritis is allowed.

    • Corrected QT interval (QTc) greater than 500 msec

    • Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study due to the possibility of pharmacokinetic interactions between antiretroviral medications and sorafenib or TRC105. HIV positive patients not receiving antiretroviral therapy are excluded due to the possibility that sorafenib or TRC105 may worsen their condition and the likelihood that the underlying condition may obscure the attribution of adverse events with respect to sorafenib or TRC105.

    • History of hypersensitivity reaction to human or mouse antibody products

    • Patients with a history of familial bleeding disorders

    • Patients with a history of hereditary hemorrhagic telangiectasia (Osler-Weber- Rendu Syndrome).

    • Pregnancy and breast feeding are exclusion factors. Enrolled patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, the duration of study participation and 3 months after the end of the treatment.

    • Patients with unhealed wounds for more than 30 days.

    INCLUSION OF WOMEN AND MINORITIES:

    -Men and women of all races and ethnic groups are eligible for this trial.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Tim F Greten, M.D., National Cancer Institute (NCI)

    Study Documents (Full-Text)

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Tim Greten, M.D., Principal Investigator, National Institutes of Health Clinical Center (CC)
    ClinicalTrials.gov Identifier:
    NCT01306058
    Other Study ID Numbers:
    • 110102
    • 11-C-0102
    First Posted:
    Mar 1, 2011
    Last Update Posted:
    Jan 23, 2019
    Last Verified:
    Jan 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Tim Greten, M.D., Principal Investigator, National Institutes of Health Clinical Center (CC)
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail 27 patients were enrolled. One patient signed consent but developed rapid disease progression and did not receive any treatment.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Period Title: Overall Study
    STARTED 27
    COMPLETED 25
    NOT COMPLETED 2

    Baseline Characteristics

    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Overall Participants 27
    Age (Count of Participants)
    <=18 years
    0
    0%
    Between 18 and 65 years
    25
    92.6%
    >=65 years
    2
    7.4%
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    55.3
    (13)
    Sex: Female, Male (Count of Participants)
    Female
    7
    25.9%
    Male
    20
    74.1%
    Ethnicity (NIH/OMB) (Count of Participants)
    Hispanic or Latino
    1
    3.7%
    Not Hispanic or Latino
    26
    96.3%
    Unknown or Not Reported
    0
    0%
    Race (NIH/OMB) (Count of Participants)
    American Indian or Alaska Native
    1
    3.7%
    Asian
    2
    7.4%
    Native Hawaiian or Other Pacific Islander
    0
    0%
    Black or African American
    10
    37%
    White
    13
    48.1%
    More than one race
    0
    0%
    Unknown or Not Reported
    1
    3.7%
    Region of Enrollment (Count of Participants)
    United States
    27
    100%
    Participant Etiology of Hepatocellular Cancer (HCC) (Count of Participants)
    Hepatitis B Virus (HBV)
    3
    11.1%
    Hepatitis C Virus (HCV)
    15
    55.6%
    Cryptogenic
    6
    22.2%
    Hematochromatosis
    1
    3.7%
    Baseline Child Pugh Score (Count of Participants)
    Child Pugh Score - 5
    10
    37%
    Child Pugh Score - 6
    4
    14.8%
    Child Pugh Score - 7
    1
    3.7%
    NA
    10
    37%
    Number of Participants with Extrahepatic disease (Count of Participants)
    Yes
    17
    63%
    No
    8
    29.6%
    Prior Therapies (Count of Participants)
    No prior intervention
    9
    33.3%
    ≥2 locoregional procedures
    7
    25.9%
    Previous TACE
    8
    29.6%
    Surgery
    5
    18.5%
    Ablation
    2
    7.4%
    Radioembolization
    2
    7.4%
    Transplant
    2
    7.4%
    Number of Participants with Liver Cirrhosis (Count of Participants)
    Yes
    15
    55.6%
    No
    10
    37%
    Eastern Cooperative Oncology Group (ECOG) Performance Status (Count of Participants)
    Grade 0
    8
    29.6%
    Grade 1
    17
    63%
    Participants with Hepatocellular Cancer & Fibrolamellar (Count of Participants)
    Hepatocellular Cancer (HCC)
    24
    88.9%
    Fibrolamellar
    1
    3.7%

    Outcome Measures

    1. Primary Outcome
    Title Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC)
    Description MTD is the highest dose studied for which the incidence of DLT was less than 33%. DLT criteria included treatment-related grade 3 non-hematological toxicities or grade 4 hematological toxicities occurring within the first 28 days of treatment. Grade 3 electrolyte toxicities to be corrected to Grade 1 or less within 24 hours will be considered dose limiting (proteinuria >3.5g/24 hour will be defined as a DLT). Drug-related Grade 4 hematological toxicity will be considered dose limiting. Toxicity requiring a dose reduction or a delay in treatment for >7 days will be considered dose limiting. Other Grade 3 or higher toxicity related to TRC105 will be considered dose limiting.
    Time Frame Completed in the first 28 days of treatment (cycle 1)

    Outcome Measure Data

    Analysis Population Description
    24/27 analyzed. One patient signed consent but developed rapid disease progression and did not receive any treatment. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 24
    Number [mg/kg]
    15
    2. Primary Outcome
    Title Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC)
    Description TTP is the time between the first day of treatment to the day of disease progression. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).
    Time Frame 2 years

    Outcome Measure Data

    Analysis Population Description
    24/27 analyzed. One patient signed consent but developed rapid disease progression and did not receive any treatment. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 24
    Median (95% Confidence Interval) [Months]
    3.8
    3. Secondary Outcome
    Title Overall Response Rate (ORR) as Determined by the Standard Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
    Description Overall response (Complete Response (CR) + Partial Response (PR) was assessed by the Standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria for target lesions and assessed by magnetic resonance imaging (MRI). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter of target lesions.
    Time Frame 2 years

    Outcome Measure Data

    Analysis Population Description
    24/27 analyzed. One patient signed consent but developed rapid disease progression and did not receive any treatment. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 24
    Number (95% Confidence Interval) [percentage of participants]
    21
    77.8%
    4. Secondary Outcome
    Title Overall Response Rate (ORR) as Determined by the European Association for the Study of the Liver (EASL)-Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
    Description Overall response (Complete Response (CR) + Partial Response (PR) was assessed by the European Association for the Study of the Liver (EASL)-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for target lesions and assessed by magnetic resonance imaging (MRI). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter of target lesions.
    Time Frame 2 years

    Outcome Measure Data

    Analysis Population Description
    24/27 analyzed. One patient signed consent but developed rapid disease progression and did not receive any treatment. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 24
    Number (95% Confidence Interval) [percentage of participants]
    21
    77.8%
    5. Secondary Outcome
    Title Patients Who Developed Antidrug Antibodies
    Description Patients who develop antidrug antibodies is measured by human anti-chimeric antibody (HACA) formation (e.g. immunogenicity of TRC105).
    Time Frame Cycle 1 Day 1, 28 days post end of study (up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    11/27 were analyzed because only 11 patients were evaluable at the highest dose level given to patients.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 11
    Count of Participants [Participants]
    7
    25.9%
    6. Secondary Outcome
    Title Immunogenicity of TRC105 as Measured by Human Anti-mouse Antibody (HAMA) Formation
    Description A 5mL blood sample will be collected to assess immunogenicity. Immunogenicity will be measured by the enzyme-linked immunosorbent assay (ELISA) and expressed in titres. The higher the titre, the higher the formation of HAMA antibody in the blood. A higher concentration of HAMA (higher titre result) is a negative finding. A higher level means the drug elimination is faster and the TRC 105 is then less effective. Lower level is 0-2 titre. Any value above 2 titre would be a positive HAMA result. The HAMA ( Human anti-mouse antibody) measurement at 28 days post treatment levels provides information as to the rate of drug elimination and effectiveness. Patients with 0 to < 2.0 titre. eliminates the TRC 105 slower and the drug may be more effective than patients who have a low(>2.0 titres) or high level of HAMA. Higher levels of HAMA reflect the TRC 105 elimination from the body faster and the drug potentially not as effective as negative HAMA titres.
    Time Frame Baseline and then 28 days following the end of the study treatment, approximately two years

    Outcome Measure Data

    Analysis Population Description
    9/20, 8/20, and 3/20 participants were evaluable for the noted time periods below.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 20
    Baseline
    0.02
    no evidence of HAMA 28 days post treatment
    0
    Low level of HAMA 28 days post treatment
    65
    High level of HAMA 28 days post treatment
    515
    7. Secondary Outcome
    Title Number of Participants With Serious and Non-serious Adverse Events by Common Terminology Criteria in Adverse Events (CTCAE)v4.0
    Description Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
    Time Frame 4 years and 10.5 months

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 27
    Count of Participants [Participants]
    27
    100%
    8. Secondary Outcome
    Title Number of Participants With Dose Limiting Toxicity (DLT)
    Description DLT was assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0. DLT criteria included treatment-related grade 3 non-hematological toxicities or grade 4 hematological toxicities occurring within the first 28 days of treatment. Grade 3 electrolyte toxicities to be corrected to Grade 1 or less within 24 hours will be considered dose limiting (proteinuria >3.5g/24 hour will be defined as a DLT). Drug-related Grade 4 hematological toxicity will be considered dose limiting. Toxicity requiring a dose reduction or a delay in treatment for >7 days will be considered dose limiting. Other Grade 3 or higher toxicity related to TRC105 will be considered dose limiting.
    Time Frame First 28 days of treatment (cycle 1)

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 27
    Count of Participants [Participants]
    1
    3.7%
    9. Secondary Outcome
    Title Treatment-emergent Adverse Events
    Description Here are the number of treatment-emergent adverse events categorized by Any grade, Grade 3, Grade 4 and Grade 5 adverse events. Adverse events was assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0. Grade 1 is mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 is moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) (e.g. preparing meals, shopping for groceries or clothes). Grade 3 is severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL (e.g. bathing, dressing and undressing). Grade 4 is life-threatening consequences; urgent intervention indicated. Grade 5 is death related to adverse event.
    Time Frame 4 years and 10.5 months

    Outcome Measure Data

    Analysis Population Description
    25/27 analyzed. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 25
    Any Grade Headache
    20
    Any Grade Epistaxis
    19
    Any Grade Increased aspartate aminotransaminase
    18
    Grade 3 Increased aspartate aminotransaminase
    5
    Any Grade Rash, other
    18
    Grade 3 Rash, other
    3
    Any Grade Hypophosphatemia
    18
    Grade 3 Hypophosphatemia
    7
    Any Grade Hypoalbuminemia
    17
    Grade 3 Hypoalbuminemia
    2
    Any Grade Anemia
    16
    Grade 3 Anemia
    1
    Any Grade Fatigue
    15
    Any Grade Increased alkaline phosphatase
    15
    Grade 3 Increased alkaline phosphatase
    5
    Any Grade Diarrhea
    15
    Grade 3 Diarrhea
    1
    Any Grade Increased blood bilirubin
    14
    Grade 3 Increased blood bilirubin
    6
    Grade 4 Increased blood bilirubin
    1
    Any Grade Nausea
    14
    Any Grade Increased alanine transaminase
    13
    Any Grade Oral mucositis/pain
    12
    Any Grade Thrombocytopenia
    10
    Grade 3 Thrombocytopenia
    1
    Any Grade Amylase
    10
    Grade 3 Amylase
    2
    Grade 4 Amylase
    1
    Any Grade Abdominal pain
    9
    Any Grade Hand-foot skin reaction
    8
    Grade 3 Hand-foot skin reaction
    2
    Any Grade Infusion reaction
    8
    Grade 3 infusion reaction
    1
    Any Grade Neutropenia
    8
    Any Grade Weight loss
    8
    Any Grade Hypertension
    6
    Grade 3 Hypertension
    1
    Any Grade Vomiting
    6
    Any Grade Hypomagnesemia
    5
    Any Grade Alopecia
    5
    Any Grade Insomnia
    4
    Any Grade Constipation
    3
    Grade 3 Intracranial hemorrhage
    1
    Grade 5 Myocardial ischemia
    1
    Grade 4 Lipase
    1
    Any Grade Hyperglycemia
    1
    Grade 3 Hyperglycemia
    2
    Grade 4 Hyperuricemia
    2
    10. Secondary Outcome
    Title Median Progression-free Survival (PFS)
    Description PFS was calculated from the on-study date until date of progression, death, or an event that would render the patient inevaluable for further follow-up (liver dysfunction), or end of study. Probabilities were determined using the Kaplan-Meier method. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).
    Time Frame up to 6 months

    Outcome Measure Data

    Analysis Population Description
    25/27 analyzed. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 25
    Median (95% Confidence Interval) [Months]
    3.8
    11. Secondary Outcome
    Title Percentage of Participants With Progression Free Survival (PFS) at 3 and 6 Months
    Description Percentage of participants who were progression free at 3 and 6 months. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).
    Time Frame 3 and 6 months

    Outcome Measure Data

    Analysis Population Description
    25/27 analyzed. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 25
    3 month PFS
    75.0
    277.8%
    6 month PFS
    16.7
    61.9%
    12. Secondary Outcome
    Title Median Overall Survival (OS)
    Description OS was calculated from the on-study date until the date of death or the date the patient was last known to be alive. Probabilities were determined using the Kaplan-Meier method.
    Time Frame up to 2 years

    Outcome Measure Data

    Analysis Population Description
    25/27 analyzed. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 25
    Median (95% Confidence Interval) [Months]
    15.5
    13. Secondary Outcome
    Title Percentage of Participants With Overall Survival (OS) at 6 and 12 Months
    Description Percentage of participants last known to be alive at 6 and 12 months.
    Time Frame 6 and 12 months

    Outcome Measure Data

    Analysis Population Description
    25/27 analyzed. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 25
    6 month OS
    74.0
    274.1%
    12 month OS
    59.2
    219.3%
    14. Secondary Outcome
    Title Number of Participants With Stable Disease, Partial Response, and Progressive Disease on Phase I and Phase II of the Clinical Trial
    Description Response is defined as per the Response Evaluation Criteria in Solid Tumors (RECIST). Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. To be assigned a confirmed PR, changes in tumor measurements must be confirmed by repeat assessments that should be performed at least 4 weeks after the criteria for response are first met. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions).
    Time Frame Every 8 weeks, up to 180 days

    Outcome Measure Data

    Analysis Population Description
    7/27 participants were not evaluable (1 was not evaluable, 1 patient had dose limiting toxicity myocardial infarction, 1 could not tolerate sorafenib, 1 infusion reaction to TRC105 during first dose, 1 early progressive disease, 1 side effects, and 1 off due to severe skin toxicity).
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 20
    Phase I - Stable disease
    9
    33.3%
    Phase I - Progressive disease
    2
    7.4%
    Phase I - Partial response
    4
    14.8%
    Phase 2 - Stable disease
    3
    11.1%
    Phase 2 - Partial response
    1
    3.7%
    Phase 2 - Progressive disease
    2
    7.4%
    15. Secondary Outcome
    Title Area Under the Plasma Concentration
    Description Mean peak TRC105 serum trough concentrations were plotted over time by dose level to assess accumulation. (e.g. drug absorption). The lower limit of quantification (LLOQ) is 200 ng/mL.
    Time Frame Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, and prior to start of TRC105 infusion

    Outcome Measure Data

    Analysis Population Description
    24/27 analyzed. One patient signed consent but developed rapid disease progression and did not receive any treatment. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 24
    Dose level 1
    75933
    Dose level 2
    152900
    Dose level 3
    242882
    Dose level 4
    362611
    16. Secondary Outcome
    Title Changes in Biomarkers Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF)
    Description Plasma biomarker tests were performed for VEGF and PIGF using assay plates from Meso-Scale Discovery according to the product manual. The concentrations of the cytokines were determined with recombinant standards. Changes in biomarkers were determined by a Wilcoxon signed rank test.
    Time Frame Cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, or end of study, an average of 12 weeks

    Outcome Measure Data

    Analysis Population Description
    25/27 analyzed. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 25
    VEGF cycle 1 day 1
    202.5
    PIGF cycle 1 day 1
    44.6
    VEGF cycle 1 day 15
    299
    PIGF cycle 1 day 15
    81.6
    VEGF cycle 2 day 1
    243.4
    PIGF cycle 2 day 1
    68.8
    VEGF end of study (eos)
    184.3
    PIGF end of study (eos)
    53.5
    Statistical Analysis 1
    Statistical Analysis Overview Comparison Group Selection Sorafenib & TRC105 in Hepatocellular CA
    Comments
    Type of Statistical Test Non-Inferiority
    Comments Paired T-test. Two tailed.
    Statistical Test of Hypothesis p-Value <0.05
    Comments
    Method Wilcoxon signed rank test
    Comments
    17. Secondary Outcome
    Title Changes in Biomarker Cluster of Differentiation 105 (CD105)
    Description Blood samples were collected and analyzed by the enzyme-linked immunosorbent assay (ELISA). Serum samples were measured using a validated ELISA with a lower limit of quantification (LLOQ) of 200 ng/ml. Soluble endoglin was only assessed in patient samples without detectable TRC105 concentrations.
    Time Frame Cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, or end of study (eos), an average of 12 weeks

    Outcome Measure Data

    Analysis Population Description
    25/27 analyzed. One patient developed a fatal myocardial infarction and one patient developed a grade 3 cerebral tumor hemorrhage.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 25
    Cycel 1 Day 1
    27.5
    Cycle 1 Day 15
    60.4
    Cycel 2 day 1
    64.5
    End of study (eos)
    66.6
    Statistical Analysis 1
    Statistical Analysis Overview Comparison Group Selection Sorafenib & TRC105 in Hepatocellular CA
    Comments
    Type of Statistical Test Non-Inferiority
    Comments Paired T-test. Two tailed.
    Statistical Test of Hypothesis p-Value <0.0001
    Comments Cycle 1 day 15 vs. cycle 1 day 1
    Method Wilcoxon signed rank test
    Comments
    Statistical Analysis 2
    Statistical Analysis Overview Comparison Group Selection Sorafenib & TRC105 in Hepatocellular CA
    Comments
    Type of Statistical Test Non-Inferiority
    Comments Cycle 2 day 1 vs. cycle 1 day 1. Paired T-test. Two tailed.
    Statistical Test of Hypothesis p-Value <0.0001
    Comments
    Method Wilcoxon signed rank test
    Comments
    Statistical Analysis 3
    Statistical Analysis Overview Comparison Group Selection Sorafenib & TRC105 in Hepatocellular CA
    Comments
    Type of Statistical Test Non-Inferiority
    Comments eos (end of study) vs. cycle 1 day 1. Paired T-test. Two tailed.
    Statistical Test of Hypothesis p-Value 0.0009
    Comments
    Method Wilcoxon signed rank test
    Comments
    18. Secondary Outcome
    Title Percentage Signal Change in Response on Magnetic Resonance Imaging (MRI)
    Description The perfusion of tumors was evaluated and analysis of normalized signal intensity in unenhanced and enhanced MRIs at each time point with calculation of measured percentage of signal change to reflect tumor vascularity. Signal change and signal intensity is defined as the Initial Area Under the Gd Curve measured over 60 seconds (IAUC60) and the Transport Constant (Ktrans) and the difference in these values relative to baseline.
    Time Frame Baseline and Cycle 1 Day 2 and Cycle 2 Day 1, an average of 12 weeks

    Outcome Measure Data

    Analysis Population Description
    This analysis was not done as magnetic resonance imaging (MRI) scans not performed as planned.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    Measure Participants 0

    Adverse Events

    Time Frame 4 years and 10.5 months
    Adverse Event Reporting Description 16 deaths are not included in the serious adverse event table because this study was originally not under the death related to disease serous adverse event. The deaths were reported in the continuing reviews.
    Arm/Group Title Sorafenib & TRC105 in Hepatocellular CA
    Arm/Group Description CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
    All Cause Mortality
    Sorafenib & TRC105 in Hepatocellular CA
    Affected / at Risk (%) # Events
    Total 16/27 (59.3%)
    Serious Adverse Events
    Sorafenib & TRC105 in Hepatocellular CA
    Affected / at Risk (%) # Events
    Total 11/27 (40.7%)
    Cardiac disorders
    Left ventricular systolic dysfunction 1/27 (3.7%) 1
    Myocardial infarction 1/27 (3.7%) 1
    Gastrointestinal disorders
    Diarrhea 1/27 (3.7%) 1
    Gastrointestinal pain 1/27 (3.7%) 1
    Mucositis oral 1/27 (3.7%) 1
    Pancreatitis 1/27 (3.7%) 1
    General disorders
    Fever 1/27 (3.7%) 1
    Infusion related reaction 1/27 (3.7%) 1
    Hepatobiliary disorders
    Hepatic failure 1/27 (3.7%) 2
    Infections and infestations
    Lung infection 1/27 (3.7%) 1
    Sepsis 1/27 (3.7%) 1
    Investigations
    Aspartate aminotransferase increased 1/27 (3.7%) 1
    Blood bilirubin increased 1/27 (3.7%) 1
    Lipase increased 1/27 (3.7%) 3
    Serum amylase increased 1/27 (3.7%) 1
    Nervous system disorders
    Intracranial hemorrhage 1/27 (3.7%) 1
    Stroke 1/27 (3.7%) 1
    Respiratory, thoracic and mediastinal disorders
    Epistaxis 1/27 (3.7%) 1
    Skin and subcutaneous tissue disorders
    Rash maculo-papular 2/27 (7.4%) 2
    Vascular disorders
    Flushing 1/27 (3.7%) 1
    Hypotension 1/27 (3.7%) 1
    Other (Not Including Serious) Adverse Events
    Sorafenib & TRC105 in Hepatocellular CA
    Affected / at Risk (%) # Events
    Total 27/27 (100%)
    Blood and lymphatic system disorders
    Anemia 21/27 (77.8%) 62
    Cardiac disorders
    Chest pain - cardiac 1/27 (3.7%) 1
    Sinus tachycardia 1/27 (3.7%) 1
    Ear and labyrinth disorders
    Ear pain 1/27 (3.7%) 1
    Eye disorders
    Eye disorders - Other, Bleeding; Puffy eyelids 2/27 (7.4%) 2
    Gastrointestinal disorders
    Abdominal distension 2/27 (7.4%) 2
    Abdominal pain 2/27 (7.4%) 2
    Ascites 4/27 (14.8%) 5
    Bloating 1/27 (3.7%) 1
    Constipation 3/27 (11.1%) 3
    Diarrhea 13/27 (48.1%) 31
    Dry mouth 2/27 (7.4%) 2
    Dysphagia 1/27 (3.7%) 1
    Enterocolitis 1/27 (3.7%) 1
    Enterocolitis infectious 1/27 (3.7%) 1
    Gastrointestinal disorders - Other, specify 3/27 (11.1%) 6
    Gastrointestinal pain 1/27 (3.7%) 1
    Gastroparesis 1/27 (3.7%) 1
    Gingival pain 4/27 (14.8%) 4
    Hemorrhoidal hemorrhage 1/27 (3.7%) 1
    Mucositis oral 4/27 (14.8%) 8
    Nausea 13/27 (48.1%) 26
    Oral hemorrhage 3/27 (11.1%) 4
    Oral pain 1/27 (3.7%) 1
    Periodontal disease 2/27 (7.4%) 2
    Rectal fistula 1/27 (3.7%) 1
    Rectal hemorrhage 1/27 (3.7%) 1
    Toothache 2/27 (7.4%) 2
    Vomiting 6/27 (22.2%) 12
    General disorders
    Chills 1/27 (3.7%) 1
    Edema limbs 5/27 (18.5%) 8
    Fatigue 17/27 (63%) 25
    Fever 8/27 (29.6%) 9
    Flu like symptoms 2/27 (7.4%) 2
    Gait disturbance 1/27 (3.7%) 1
    General disorders and administration site conditions - Other, specify 1/27 (3.7%) 1
    Infusion related reaction 8/27 (29.6%) 11
    Malaise 2/27 (7.4%) 6
    Pain 18/27 (66.7%) 47
    Hepatobiliary disorders
    Bile duct stenosis 1/27 (3.7%) 1
    Infections and infestations
    Bronchial infection 1/27 (3.7%) 1
    Infections and infestations - Other, specify 5/27 (18.5%) 10
    Lung infection 1/27 (3.7%) 2
    Rhinitis infective 1/27 (3.7%) 1
    Sinusitis 1/27 (3.7%) 1
    Skin infection 1/27 (3.7%) 2
    Upper respiratory infection 3/27 (11.1%) 3
    Urinary tract infection 2/27 (7.4%) 2
    Investigations
    Activated partial thromboplastin time prolonged 12/27 (44.4%) 27
    Alanine aminotransferase increased 16/27 (59.3%) 45
    Alkaline phosphatase increased 17/27 (63%) 41
    Aspartate aminotransferase increased 18/27 (66.7%) 62
    Blood bilirubin increased 17/27 (63%) 60
    Creatinine increased 6/27 (22.2%) 10
    Fibrinogen decreased 1/27 (3.7%) 2
    Lipase increased 1/27 (3.7%) 1
    Lymphocyte count decreased 17/27 (63%) 50
    Neutrophil count decreased 6/27 (22.2%) 11
    Platelet count decreased 10/27 (37%) 23
    Serum amylase increased 12/27 (44.4%) 31
    Weight loss 1/27 (3.7%) 1
    White blood cell decreased 10/27 (37%) 26
    Metabolism and nutrition disorders
    Anorexia 8/27 (29.6%) 11
    Dehydration 4/27 (14.8%) 5
    Hypercalcemia 6/27 (22.2%) 7
    Hyperglycemia 2/27 (7.4%) 5
    Hyperkalemia 4/27 (14.8%) 4
    Hypermagnesemia 1/27 (3.7%) 1
    Hyperuricemia 6/27 (22.2%) 17
    Hypoalbuminemia 20/27 (74.1%) 53
    Hypocalcemia 3/27 (11.1%) 3
    Hypoglycemia 1/27 (3.7%) 1
    Hypokalemia 5/27 (18.5%) 5
    Hypomagnesemia 7/27 (25.9%) 14
    Hyponatremia 13/27 (48.1%) 28
    Hypophosphatemia 22/27 (81.5%) 56
    Musculoskeletal and connective tissue disorders
    Arthralgia 2/27 (7.4%) 2
    Myalgia 2/27 (7.4%) 2
    Pain in extremity 4/27 (14.8%) 6
    Nervous system disorders
    Cold sensitivity 1/27 (3.7%) 1
    Dizziness 2/27 (7.4%) 2
    Dysgeusia 1/27 (3.7%) 1
    Headache 17/27 (63%) 39
    Peripheral sensory neuropathy 1/27 (3.7%) 1
    Radiculitis 1/27 (3.7%) 1
    Somnolence 1/27 (3.7%) 1
    Stroke 1/27 (3.7%) 1
    Psychiatric disorders
    Insomnia 3/27 (11.1%) 3
    Renal and urinary disorders
    Proteinuria 1/27 (3.7%) 1
    Urinary retention 1/27 (3.7%) 1
    Urinary tract pain 1/27 (3.7%) 1
    Reproductive system and breast disorders
    Reproductive system and breast disorders - Other, specify 1/27 (3.7%) 1
    Vaginal hemorrhage 1/27 (3.7%) 1
    Respiratory, thoracic and mediastinal disorders
    Allergic rhinitis 1/27 (3.7%) 1
    Cough 3/27 (11.1%) 4
    Dyspnea 2/27 (7.4%) 4
    Epistaxis 17/27 (63%) 36
    Hiccups 1/27 (3.7%) 1
    Hoarseness 3/27 (11.1%) 3
    Nasal congestion 3/27 (11.1%) 4
    Respiratory, thoracic and mediastinal disorders - Other, specify 1/27 (3.7%) 1
    Sinus disorder 1/27 (3.7%) 2
    Sore throat 1/27 (3.7%) 1
    Voice alteration 2/27 (7.4%) 3
    Wheezing 1/27 (3.7%) 1
    Skin and subcutaneous tissue disorders
    Alopecia 5/27 (18.5%) 5
    Dry skin 4/27 (14.8%) 4
    Hyperhidrosis 3/27 (11.1%) 3
    Pain of skin 1/27 (3.7%) 1
    Palmar-plantar erythrodysesthesia syndrome 10/27 (37%) 27
    Pruritus 4/27 (14.8%) 5
    Rash acneiform 4/27 (14.8%) 4
    Rash maculo-papular 14/27 (51.9%) 52
    Skin and subcutaneous tissue disorders - Other, specify 3/27 (11.1%) 8
    Skin hyperpigmentation 1/27 (3.7%) 1
    Vascular disorders
    Flushing 3/27 (11.1%) 3
    Hot flashes 1/27 (3.7%) 1
    Hypertension 6/27 (22.2%) 12
    Hypotension 1/27 (3.7%) 1
    Thromboembolic event 1/27 (3.7%) 1

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Dr. Tim Greten
    Organization Principal Investigator
    Phone 301-451-4723
    Email tim.greten@nih.hhs.gov
    Responsible Party:
    Tim Greten, M.D., Principal Investigator, National Institutes of Health Clinical Center (CC)
    ClinicalTrials.gov Identifier:
    NCT01306058
    Other Study ID Numbers:
    • 110102
    • 11-C-0102
    First Posted:
    Mar 1, 2011
    Last Update Posted:
    Jan 23, 2019
    Last Verified:
    Jan 1, 2019